Etiopathogenesis of nonalcoholic steatohepatitis

Seminars in Liver Disease

Volumn 21, Issue 1, 2001, Pages 27-41

  Chitturi, S ^a   Farrell, G C ^a  

^a WESTMEAD HOSPITAL   (Australia)

Author keywords

Etiology; Nonalcoholic steatohepatitis; Pathogenesis

Indexed keywords

AMIODARONE; CORTICOSTEROID; CYTOCHROME P450 2E1; CYTOCHROME P450 ISOENZYME; DILTIAZEM; ESTROGEN; ESTROGEN DERIVATIVE; HEXESTROL BIS(2 DIETHYLAMINOETHYL) ETHER; LIPOXYGENASE; METHOTREXATE; NIFEDIPINE; PERHEXILINE; TAMOXIFEN; TOXIN;

ABETALIPOPROTEINEMIA; AGE; CELIAC DISEASE; DRUG INDUCED DISEASE; FATTY LIVER; GENDER; HEMOCHROMATOSIS; HEPATITIS; HEREDITY; HUMAN; HYPERINSULINEMIA; HYPERLIPIDEMIA; INSULIN RESISTANCE; INTESTINE BYPASS; LIPID PEROXIDATION; LIVER FIBROSIS; LIVER NECROSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OCCUPATIONAL DISEASE; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; TOTAL PARENTERAL NUTRITION; WEIGHT REDUCTION;

EID: 0035078484     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-12927     Document Type: Review

References (124)

1. Nonalcoholic steatohepatitis: Mayo clinic experiences with a hitherto unnamed disease
2. Fatty liver hepatitis and cirrhosis in obese patients
3. Diabetic hepatitis preceding the onset of glucose intolerance
4. Idiopathic steatohepatitis in childhood: A multicentre retrospective study
5. The natural history of nonalcoholic fatty liver
6. Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying liver disease
7. Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions
8. Animal models of steatosis
9. Mitochondria in steatohepatitis
10. Long-term consequences after jejunoileal bypass for morbid obesity
11. Post-jejunoileal bypass hepatic disease. Its similarity to alcoholic liver disease
12. Nonalcoholic steatohepatitis associated with small intestinal diverticulosis and bacterial overgrowth
13. Doxycycline in the prevention of hepatic dysfunction: An evaluation of its use following jejunoileal bypass in humans
14. Impaired hepatic drug metabolism after jejunoileal bypass in rats
15. Effect of improved absorption on development of jejunoileal bypass-induced liver dysfunction in rats
16. Etiology of jejunoileal bypass-induced liver dysfunction in rats
17. The metabolic consequences of jejunoileal bypass for obesity
18. A jejunoileal bypass rat model for rapid study of the effects of vitamin malabsorption
19. Obesity: Effects on the liver and gastrointestinal system
20. Nonalcoholic steatohepatitis: Association with obesity and insulin resistance, and influence of weight loss
21. Liver injury with alcoholic hyaline after intestinal resection
22. Injury produced by free fatty acids to lysosomes and mitochondria in cultured heart muscle and endothelial cells
23. Tumor necrosis factor-α. A key component of the obesity-diabetes link
24. Obesity increases sensitivity to endotoxin liver injury: Implications for the pathogenesis of steatohepatitis
25. Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion
26. Stabilization of cytochrome P450j messenger ribonucleic acid in the diabetic rat
27. Mechanism of induction of cytochrome P-450ac (P-450j) in chemically induced and spontaneously diabetic rats
28. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia and tumour necrosis factor alpha in the pathogenesis of nonalcoholic steatohepatitis
29. Induction mechanisms of cytochrome P450 2E1 in liver: Interplay between ethanol treatment and starvation
30. Hepatobiliary complications of total parenteral nutrition
31. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis
32. Hepatic iron and nonalcoholic fatty liver disease
33. Severe insulin resistance syndromes and nonalcoholic steatohepatitis
34. Treatment of nonalcoholic fatty liver: Present and emerging therapies
35. Effect of weight reduction on hepatic abnormalities in overweight patients
36. The possible occurrence of 'alcoholic hepatitis' in a patient with bulimia in the absence of diagnostic alcoholism
37. Fasting in obesity. Another cause of liver injury with alcoholic hyaline?
38. Does long-term home parenteral nutrition in adult patients cause chronic liver disease?
39. Severe hepatocellular reaction resembling alcoholic hepatitis with cirrhosis after massive small bowel resection and prolonged total parenteral nutrition
40. Histopathologic analysis of suspected amiodarone hepatotoxicity
41. Amiodarone-induced hepatic phospholipidosis: Correlation of morphological and biochemical findings in an animal model
42. Amiodarone hepatotoxicity: Prevalence and clinicopathologic correlations among 104 patients
43. Amiodarone hepatotoxicity simulating alcoholic liver disease
44. Perhexiline maleate-induced cirrhosis
45. Nonalcoholic steatohepatitis induced by massive doses of synthetic estrogen
46. Tamoxifen-associated steatohepatitis - Report of three cases
47. Tamoxifen-induced fatty liver in patients with breast cancer
48. Tamoxifen-induced steatohepatitis
49. Tamoxifen-induced steatohepatitis
50. Cirrhosis with steatohepatitis after adjuvant tamoxifen
51. Tamoxifen-induced nonalcoholic steatohepatitis and bezafibrate
52. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis
53. Tous les inhibiteurs calciques peuvent-ils entrainer des lésions d'hépatite alcoolique?
54. Alcoholic-like liver lesions induced by nifedipine
55. Clinical and pathologic characteristics associated with occupational exposure to dimethylformamide
56. Nonalcoholic steatohepatitis: A toxic liver disease in industrial workers
57. Clinico-biochemical evolution and late hepatic lesions in the toxic oil syndrome
58. Insulin resistance in obesity: Metabolic mechanisms and measurement methods
59. Steatohepatitis associated with limb lipodystrophy
60. Nonalcoholic steatohepatitis in children
61. Massive hepatic steatosis complicating adult celiac disease: Report of a case and review of the literature
62. Prevalence of serum antiendomysial antibodies in patients with nonalcoholic steatohepatitis
63. Liver ultrastructure in abetalipoproteinemia: Evolution of micronodular cirrhosis
64. Abetalipoproteinemia: Report of 2 cases and review of therapy
65. Histology of the liver in Wilson's disease: A study of 34 cases
66. Copper-associated liver disease in childhood
67. Long term survival in Indian childhood cirrhosis treated with D-penicillamine
68. Nonalcoholic steatohepatitis
69. Review: Nonalcoholic steatohepatitis
70. Nonalcoholic steatohepatitis (NASH): A disease of emerging identity and importance
71. Nonalcoholic steatohepatitis: An expanded clinical entity
72. Fatty liver hepatitis and type 5 hyperlipoproteinemia in juvenile diabetes mellitus. Case report and review of the literature
73. Pericentral hepatic fibrosis and intracellular hyalin in diabetes mellitus
74. Liver diseases and diabetes mellitus
75. Association of diabetes mellitus and chronic hepatitis C virus infection
76. Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis
77. Fatty liver hepatitis (steatohepatitis) and obesity: An autopsy study with analysis of risk factors
78. Lipid peroxidation and activity of antioxidant enzymes in diabetic rats
79. Host genetic factors influence disease progression in chronic hepatitis C
80. Cytokines in alcoholic liver disease
81. Increased monocyte nuclear factor-κB activation and tumor necrosis factor production on alcoholic hepatitis
82. Is bacterial ash the flash that ignites NASH?
83. Liver morphology in morbid obesity: A literature study
84. Liver pathology and the metabolic syndrome X in severe obesity
85. Liver fibrosis in over-weight patients
86. Excess weight risk factor for alcoholic liver disease
87. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis
88. Nonalcoholic fatty liver: Another feature of the metabolic syndrome?
89. Non-alcoholic steatohepatitis: Impaired antipyrine metabolism and hypertriglyceridaemia may be clues to its pathogenesis
90. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine non-alcoholic steatohepatitis
91. Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds
92. Prevalence of haemochromatosis gene mutations in nonalcoholic steatohepatitis
93. Which patients with hepatitis C develop liver complications?
94. Clinical and biochemical predictors of advanced fibrosis in NASH
95. Excess iron induces hepatic oxidative stress and transforming growth factor-β1 in genetic hemochromatosis
96. Iron in liver diseases other than hemochromatosis
97. A reappraisal of hepatic siderosis in patients with end-stage cirrhosis: Practical implications for the diagnosis of hemochromatosis
98. Alcohol-induced liver injury after jejunoileal bypass operation in rats
99. Methotrexate and histologic hepatic abnormalities: A meta-analysis
100. Metabolic and nutritional considerations in nonalcoholic fatty liver
101. Peroxisomal and mitochondrial fatty acid β-oxidation in mice nullizygous for both peroxisome proliferator-activated receptor α and peroxisomal fatty acy1-CoA oxidase
102. Steatohepatitis, spontaneous peroxisomal proliferation and liver tumors in mice lacking peroxisomal fatty acy1-CoA oxidase. Implications for peroxisomal proliferator-activated receptor α natural ligand metabolism
103. Association of nonalcoholic fatty liver disease with insulin resistance
104. Altered hepatic lymphocyte subpopulations in obesity-related murine fatty livers: Potential mechanism for sensitization to liver damage
105. Gender-dependent alterations in serum leptin in alcoholic cirrhosis
106. An increase of circulating leptin levels in patients with liver cirrhosis
107. Hepatocyte cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis
108. Induction of cytochrome P450IIE1 in the obese overfed rat
109. Rat-liver microsomal NADPH-supported oxidase activity and lipid peroxidation dependent on ethanol-inducible cytochrome P-450(P-450 IIE1)
110. Marked enhanced cytochrome P450 2E1 induction and lipid peroxidation is associated with severe liver injury in fish oil-ethanol-fed rats
111. Increased hepatocyte CYP 2E1 expression in a rat nutritional model of hepatic steatosis with inflammation
112. The rat nutritional model of nonalcoholic steatohepatitis: Strain and gender studies
113. Constitutive and inducible expression of hepatic CYP2E1 and CYP4A in leptin-deficient ob/ob mice
114. CYP2E1 is not involved in early alcohol-induced liver injury
115. Regulation of peroxisome proliferator activated receptor α mediated pathways in alcohol fed cytochrome P450 deficient mice
116. Altered expression of hepatic CYP2E1 and CYP4A in obese, diabetic ob/ob mice and fa/fa Zucker rats
117. Oxidant stress in rat liver after lipopolysaccharide administration: Effect of inducible nitric-oxide synthase inhibition
118. Mitochondrial glutathione: Importance and transport
119. Mitochondrial adaptations to obesity-related oxidant stress
120. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity
121. Leptin and TNF alpha levels in hepatitis C and its relationship with hepatic fibrosis
122. Leptin in cirrhotic patients
123. Transdifferentiation of rat hepatic stellate cells results in leptin expression